Equity Details
Price & Market Data
Price: $1.21
Daily Change: +$0.03 / 2.48%
Daily Range: $1.13 - $1.21
Market Cap: $105,607,656
Daily Volume: 678,598
Performance Metrics
1 Week: -4.84%
1 Month: 21.10%
3 Months: 3.51%
6 Months: -28.92%
1 Year: 261.0%
YTD: -12.59%
About Cognition Therapeutics, Inc. (CGTX)
Stock insights for Cognition Therapeutics, Inc. (CGTX). Price: 1.21, daily change: +$0.03 / 2.48%. Market cap: 105,607,656. Performance 3-month, 6-month, 1-year.
Company Details
Employees: 14
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. Cognition Therapeutics, Inc. was incorporated in 2007 and is based in Purchase, New York.